Dianthus Therapeutics Has Appreciated 13-Fold Over Two Years. What's Going On?

Core Viewpoint - Dianthus Therapeutics' stock experienced a significant increase following the announcement of advancing its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [1] Group 1 - The company is progressing with its CIDP treatment, which has positively impacted its stock performance [1]